Suspected Choledocholithiasis in 2026: Who Goes Straight to ERCP, Who Needs EUS or MRCP First

---

Why not just do the ERCP?

Because most intermediate-probability ducts are empty, and ERCP still injures people. ASGE 2019 puts ERCP adverse events at 6 to 15 percent. Post-ERCP pancreatitis is the one you will see this month. Rectal NSAIDs, wire-guided cannulation, and pancreatic stents belong on the PEP page. They do not make a negative diagnostic ERCP a good test.

The 2010 ASGE predictors sent too many empty ducts to the duodenoscope. He and colleagues (2017) found the old high-risk bundle had specificity 74% and PPV 64%. Tightening high probability to a seen stone or bilirubin >4 mg/dL plus dilation raised specificity to 94% and PPV to 85%. That is why the 2019 table requires both the high bilirubin and the dilated duct. Isolated bilirubin >4, or isolated dilation, is intermediate.

This page is the triage. Cannulation, stone clearance, and 30-day harm live on the ERCP quality page. Balloon vs basket vs EPLBD live on the extraction page.

What is high probability in 2019?

ASGE Standards of Practice (Buxbaum, GIE 2019, PMID 30979521), Table 15:

• CBD stone on transabdominal US or cross-sectional imaging. You already have the diagnosis. Go treat it.
• Ascending cholangitis. The indication is drainage, not stone probability. Do not wait for EUS.
• Total bilirubin >4 mg/dL and a dilated CBD (>6 mm with the gallbladder in situ). Both, not either.

ESGE 2019 (Manes, Endoscopy 2019, PMID 30943551) is the same idea in different clothes: EUS or MRCP when suspicion persists after transabdominal US, and ERCP when the stone is shown or the patient is septic from the duct. Do not treat the two documents as a fight.

What counts as intermediate?

Any one of: abnormal liver biochemical tests, age >55 years, or a dilated CBD on imaging, and none of the high-probability items. Likelihood of a persistent stone sits in the 10 to 50 percent band. That is too high to ignore and too low to accept ERCP harm as the first test.

Confirm with:

• Linear EUS from the bulb and D2. Small stones and sludge are the EUS edge.
• MRCP when MRI is available, the patient will hold still, and there is no pacemaker, severe claustrophobia, or other contraindication.
• Intraoperative cholangiography or laparoscopic US if the patient is already booked for cholecystectomy and your surgeons do them well.

Gallstone pancreatitis dropped off the intermediate list. Use the same high-probability rules. Pain and lipase without cholangitis and without a seen stone is not an ERCP.

EUS or MRCP, which one tonight?

Meeralam, Al-Shammari, and Yaghoobi (GIE 2017, PMID 28645544) pooled five prospective head-to-head studies (272 patients). EUS sensitivity 0.97 (0.91-0.99) vs MRCP 0.87 (0.80-0.93). Specificity 0.90 vs 0.92. Diagnostic odds ratio favored EUS. The sensitivity gap is mostly small stones.

Jagtap and colleagues (Gut 2022, PMID 35144973) then randomized 224 ESGE-intermediate patients. Prevalence of stones was about 50 percent. Sensitivity of both tests sat in the 92 to 98 percent range. Few false-negative ERCPs withheld (EUS 2, MRCP 5) and few unnecessary ERCPs (EUS 1, MRCP 2). Negative predictive value favored EUS. The trial's message is not 'MRCP is useless.' It is that both tests, done well, keep diagnostic ERCP rare. Pick the one you can schedule, that the patient can complete, and that you can act on.

Practical split:

• Choose EUS when small-stone risk is high, MRI is slow or contraindicated, or you can do same-session ERCP.
• Choose MRCP when EUS skill or anesthesia time is the bottleneck, the patient prefers a non-endoscopic test, or you need a map of the whole biliary tree including intrahepatics.
• If the first test is negative and the labs keep climbing or the duct keeps dilating, do not declare victory. Repeat imaging or go to IOC. A passed stone can also look like a negative test.

When do I swap scopes in the same room?

When linear EUS shows a stone or definite sludge in a symptomatic patient, and the papilla is reachable. Consent for possible ERCP before the EUS. Have a duodenoscope, sphincterotome, wire, balloon, and PEP plan in the room. Then treat. Sending that patient to recover and return in three days is how stones migrate and lists double.

If EUS is negative, stop. Do not 'take a peek' with a sphincterotomy because the referring note was anxious. That peek is the diagnostic ERCP this page exists to prevent.

What about malignant obstruction?

This URL is a choledocholithiasis triage page. A mass, abrupt stricture, or double duct without stones is a different algorithm: EUS-FNA or biliary sampling, then drainage matched to resectability. Pancreatic cyst fluid is a third problem and lives on the cyst page. Do not use CEA 192 to decide about CBD stones.

Selected references

1. ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, Sultan S, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019;89:1075-1105.e15.
2. Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51:472-491.
3. Meeralam Y, Al-Shammari K, Yaghoobi M. Diagnostic accuracy of EUS compared with MRCP in detecting choledocholithiasis: a meta-analysis of diagnostic test accuracy in head-to-head studies. Gastrointest Endosc. 2017;86:986-993.
4. Jagtap N, Kumar JK, Chavan R, et al. EUS versus MRCP to perform ERCP in patients with intermediate likelihood of choledocholithiasis: a randomised controlled trial. Gut. 2022;71:2005-2010.
5. He H, Tan C, Wu J, et al. Accuracy of ASGE high-risk criteria in evaluation of patients with suspected common bile duct stones. Gastrointest Endosc. 2017;86:525-532.

---

Last reviewed September 20, 2026. Written for clinicians deciding whether tonight's dilated duct and abnormal liver tests need a duodenoscope, an echoendoscope, or an MRCP.